Literature DB >> 15927847

Acute haemodynamic effects of IL-6 treatment in vivo: involvement of vagus nerve in NO-mediated negative inotropism.

Laura Comini1, Evasio Pasini, Tiziana Bachetti, Michel Dreano, Gianni Garotta, Roberto Ferrari.   

Abstract

Interleukin-6 (IL-6) reduces myocardial haemodynamics. However, the intrinsic mechanisms of IL-6 effects are not known. We hypothesized that nitric oxide (NO) synthesised by neuronal synthase (nNOS) can be the molecular mediator of IL-6-mediated cardiac effects. Thus, we investigated in vivo after IL-6 acute administration: (1) the role of NO pathway; (2) the importance of NO derived from nNOS located in intracardiac vagal ganglion in the anterior surface of the left ventricle. Sprague-Dawley (SD) rats (225-250 g) were anaesthetized (sodium pentobarbital 30 mg/kg intraperitoneally administered) and ventilated. The effects of a single IL-6 bolus (100 microg/kg intravenously administered) were studied in four experimental groups: (a) IL-6 (n=6), (b) IL-6 plus 30 mg/kg of L-NAME (an eNOS and nNOS inhibitor; n=6), (c) IL-6 plus 25mg/kg of 7-NI (a specific nNOS inhibitor; n=6), (d) IL-6 plus vagal resection (n=6). We evaluated the following parameters: mean aortic pressure (MAP), left ventricular end systolic pressure (LVESP), left ventricular positive peak dP/dt (PP dP/dt). Data are expressed as mean+/-sem. IL-6 caused a transient but significant reduction of MAP (-21.8% of basal: p<0.05), LVESP (from 130+/-4.2 to 1056.5 mmHg: p<0.05) and PP dP/dt (from 5390+/-158 to 4400+/-223 mmHg/s, p<0.02). Concomitant treatment with L-NAME or 7-NI totally abolished IL-6 effects. Vagal resection significantly reduced the haemodynamic effects (MAP: -10% of basal: p=ns; LVEDS: from 125+/-7.3 to 117+/-6.8 mmHg, p<0.05; PP dP/dt from 5500+/-150 to 5000+/-143 mmHg/s, p<0.05). We conclude that acute administration of IL-6 caused transient but significant cardiac negative inotropism. IL-6 haemodynamic effects are partly due to NO synthesised by nNOS located in vagal left ventricular ganglia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15927847     DOI: 10.1016/j.cyto.2005.01.009

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  5 in total

Review 1.  Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies.

Authors:  Alan H Baik; Olalekan O Oluwole; Douglas B Johnson; Nina Shah; Joe-Elie Salem; Katy K Tsai; Javid J Moslehi
Journal:  Circ Res       Date:  2021-05-03       Impact factor: 23.213

2.  Interleukin-6 displays lung anti-inflammatory properties and exerts protective hemodynamic effects in a double-hit murine acute lung injury.

Authors:  Guillaume Voiriot; Keyvan Razazi; Valérie Amsellem; Jeanne Tran Van Nhieu; Shariq Abid; Serge Adnot; Armand Mekontso Dessap; Bernard Maitre
Journal:  Respir Res       Date:  2017-04-19

3.  Soluble interleukin-6 receptor in young adults and its relationship with body composition and autonomic nervous system.

Authors:  Henry H León-Ariza; Daniel A Botero-Rosas; Edward J Acero-Mondragón; Dario Reyes-Cruz
Journal:  Physiol Rep       Date:  2019-12

Review 4.  Advanced Imaging Supports the Mechanistic Role of Autoimmunity and Plaque Rupture in COVID-19 Heart Involvement.

Authors:  Maria Elena Laino; Angela Ammirabile; Francesca Motta; Maria De Santis; Victor Savevski; Marco Francone; Arturo Chiti; Lorenzo Mannelli; Carlo Selmi; Lorenzo Monti
Journal:  Clin Rev Allergy Immunol       Date:  2022-01-28       Impact factor: 8.667

Review 5.  Biological characteristics of IL-6 and related intestinal diseases.

Authors:  Yuexin Guo; Boya Wang; Tiantian Wang; Lei Gao; Ze-Jun Yang; Fei-Fei Wang; Hong-Wei Shang; Rongxuan Hua; Jing-Dong Xu
Journal:  Int J Biol Sci       Date:  2021-01-01       Impact factor: 6.580

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.